Genome-wide association studies

Karen Mohlke, PhD
Department of Genetics
University of North Carolina

Complex traits



Common and rare variants

GGATTCACTGCAAAATCG
GGATTCACTGCAAAATCG
GGATTCACAGCAAAATCG
GGATTCACTGCAAAATCG
GGATTCACTGCAAAATCG
GGATTCACTGCAAAATCG
GGATTCACTGCAAAATGG
GGATTCACAGCAAAATCG
GGATTCACAGCAAAATCG
GGATTCACTGCAAAATCG



Genetic architecture



Manolio (2009) Nature 46: 747

Genome-wide association (GWA)

- **What is the goal?**
- **How are studies performed?**
- **What can we learn from the associated regions?**
- **What do the findings tell us about disease?**

GWA Studies

- **Benefits of GWA vs classical mapping**
  - **More powerful vs linkage for common, low penetrance variants**
  - **Better resolution than linkage**
  - **No need to select candidate genes**
- **Requirements of GWA**
  - **Catalog of human genetic variants**
  - **Low cost, accurate method for genotyping**
  - **Large number of informative samples**
  - **Efficient statistical design and analysis**

Goals of a GWA study

- **Test a large portion of the common single nucleotide genetic variation in the genome for association with a disease or variation in a quantitative trait**
- **Find disease/quantitative trait-related variants without a prior hypothesis of gene function**

Steps in a GWA study

- **Samples**
- **Genotyping**
- **Quality control**
- **Statistical analysis**
- **Replication**

Phenotype

- **Disease (case/control)**
  - **Rare**
  - **Common**
- **Quantitative trait**
  - **Easy to measure: Weight, height**
  - **Requires testing: Coronary artery thickness**
  - **Requires experiment: Gene expression**

Selection of cases and controls

Cases



Controls



Definition of case?

Definition of control?

Selection of cases

Cases



- **Potential criteria to enrich genetic effect size**
  - **More severely affected individuals**
  - **Require other family member to have disease**
  - **Younger age-of-disease onset**

Selection of controls

- **Potential criteria to enrich genetic effect size**
  - **Low risk of disease rather than population-based samples**
  - **Same ancestry as cases**
  - **Matched to cases on age, sex, demographics**

Controls



Matched ancestry

Cases



Controls



Unmatched ancestry

Cases



Controls



May have inadequate ancestry information prior to genotyping

Population stratification and cryptic relatedness

- **Can produce spurious associations in case-control studies**
- **Account for or avoid**
  - **Genomic control**
  - **Principle components**
  - **Family-based study design**

Genome-wide SNP panels

- **10,000 - 1+ million SNPs**
- **Affymetrix, Illumina**
  - **Random SNPs**
  - **Selected haplotype tag SNPs**
  - **Copy number probes**

Selecting 'haplotype tag' SNPs



International HapMap Consortium (2003) Nature 426:789

Illumina Infinium Assay



Gunderson et al. (2005) NatGen 37:549

Illumina Infinium Assays



Illumina.com

Affymetrix GeneChip Array



image from affymetrix.com



Global genomic coverage

Table 1 Global coverage (%) by SNP chips

SNP chip	*CEU*	*CHB+JPT*	*YRI*
SNP Array 5.0	64	66	41
SNP Array 6.0	83	84	62
HumanHap300	77	66	29
HumanHap550	87	83	50
HumanHap650Y	87	84	60
Human1M	93	92	68

Li (2008) EJHG 16:625

Local genomic coverage



Figure 1 Local coverage map for each HapMap population for chromosome 17. The six SNP chips that were evaluated are SNP Array 5.0 (black), SNP Array 6.0 (blue), HumanHap300 (red), HumanHap550 (green), HumanHap650Y (cyan), and Human1M (purple). The red bars at the top and bottom indicate the transcription regions of known protein coding genes.

Li (2008) EJHG 16:625

Quality control: Identify and remove bad samples

- Poor quality samples
  - Sample success rate < 95 %
  - Excess heterozygous genotypes
- Sample switches
  - Wrong sex
- Unexpected related individuals
  - Pair-wise comparisons of genotype similarity
  - Duplicates
- Ancestry different from the rest of sample

Quality control: Identify and remove bad SNPs



Ideal genotyping plot Clusters mis-called Clusters overlap

McCarthy (2008) Nat Rev Gen 9:356

Quality control: Identify and remove bad SNPs

- **Genotyping success rate < 95%**
- **Different genotypes in duplicate samples**
- **Expected proportions of genotypes are not consistent with observed allele frequencies**
- **Non-Mendelian inheritance in trios**
- **Differential missingness in cases and controls**

Test for association

- **Differences between cases & controls**

	AA	AC	CC
Case			
Control			

- **Ex. Cochran-Armitage test for trend**
- **Covariates (age, sex, …)**
- **Other genetic models**

Odds ratio

- **Surrogate measure of effect of allele on risk of developing disease**

Allele	A	C	Total
Case	860	1140	2000
Control	1000	1000	2000
Total	1860	2140	4000

Odds of C allele given case status = Case C / Case A
Odds of C allele given control status = Control C / Control A

$$\text{Odds Ratio} = \frac{\text{Case C / Case A}}{\text{Control C / Control A}} = \frac{1140 / 860}{1000 / 1000} = 1.33$$

Multiple testing

- **Genotype and test > 300K – 1M SNPs**
- **Correct for the multiple tests**

$$\frac{.05\ P\text{-value}}{1\ \text{million SNPs}} = 5 \times 10^{-8}$$

- **Need large effect or large sample size**

Type 2 diabetes association results

1161 Finnish T2D cases + 1174 Finnish normal glucose tolerant controls



Logistic regression using additive model adjusted for age, gender, birth province

Which results are true positives?

1161 Finnish T2D cases + 1174 Finnish normal glucose tolerant controls



Quantile-quantile (Q-Q) plot



Before and after adjustment of population stratification



Pearson (2008) JAMA 299:1335

Power to detect association

Table 1 Power of GWASs to discover several recently defined associations

Gene	Disease	Power in a 'typical' GWAS (1,000 cases/1,000 controls) 1.0×10^{-2}	1.0×10^{-4}	1.0×10^{-8}	Sample size required for 90% power, $P < 10^{-8}$	RAF	RR
ATG16L1	CD	>0.99	>0.99	0.74	2,430	0.5	1.5
IRGM	CD	0.67	0.19	<0.01	10,902	0.075	1.4
PTPN2	T1D, CD	0.37	0.05	<0.01	19,754	0.17	1.2
IL2	T1D	0.11	<0.01	<0.01	54,600	0.26	1.1
9p21	MI	0.97	0.87	0.09	5,066	0.47	1.25
9p21	T2D	0.36	0.05	<0.01	20,220	0.83	1.2
CDKAL1	T2D	0.35	0.04	<0.01	20,700	0.31	1.15

Altshuler (2007) Nat Gen 7:813

Gain power through collaboration

- **Each study performs GWA**
- **Combine data from all studies by performing a meta-analysis**
- **Potential issues:**
  - **Different genotyping and analysis strategies**
  - **Case definitions are different**

Imputation: Observed genotypes



Li (2009) Ann Rev Genomics Hum Genet 10:387

Gonçalo Abecasis

Identify match among reference



Li (2009) Ann Rev Genomics Hum Genet 10:387

Gonçalo Abecasis

Phase chromosomes, impute missing genotypes



Li (2009) Ann Rev Genomics Hum Genet 10:387

Gonçalo Abecasis

Imputation facilitates meta-analysis



Li (2009) Ann Rev Genomics Hum Genet 10:387



Li (2009) Ann Rev Genomics Hum Genet 10:387



GWA in ~19,840 individuals
Follow-up in ~20,623 individuals

Kathiresan (2009) Nat Gen 41:56



Nat Gen 41:56



Nat Gen 41:56

Heterogeneity

- ***FTO*** **associated with type 2 diabetes in the Welcome Trust Case-Control Consortium**
- **Mostly not observed in other diabetes studies**
- **WTCCC cases more obese than controls**
- **Diabetes signal abolished when adjust for BMI**
- **ID of heterogeneity source led to BMI gene**

Frayling 2007 Science 316:889

Replication of FTO with obesity



Odds of obesity for each copy of the A allele of rs9939609

Meta-analytic OR *P*=3 x 10^{-26}

Frayling 2007 Science 316:889



Replicate known association

APOE and LDL-cholesterol



Novel signal: strongest within intron



Novel signal: outside of gene



New common variant near gene with known rare variants



Private mutations in *PCSK9* change LDL by >100 mg/dl
Abifadel et al, 2003

Rare variants (MAF 1%) in *PCSK9* can change LDL by ~16 mg/dl
Cohen et al, 2005

Common variants (MAF 20%) in *PCSK9* change LDL by ~3 mg/dl
Willer et al, 2008

Nearby independent signals



Cristen Willer

CEU: D' .07, r^2 < .01, p-values remain unchanged with other SNP as covariate

Narrower signal in older populations



Sanna (2008) Nat Gen 40:198

Signals associated with ≥2 traits

Attributed genes	Associated traits reported in catalog
PTPN22	Crohn's disease, type 1 diabetes, rheumatoid arthritis
FCER1A	Serum IgE levels, select biomarker traits (MCP1)
BCL11A	Fetal hemoglobin, F-cell distribution
GCKR	CRP, lipids, waist circumference
HLA / MHC region	Systemic lupus erythematosus, lung cancer, psoriasis, inflammatory bowel disease, ulcerative colitis, celiac disease, rheumatoid arthritis, juvenile idiopathic arthritis, multiple sclerosis, type 1 diabetes
CDKAL1	Crohn's disease, type 2 diabetes
IRF4	Freckles, hair color, chronic lymphocytic leukemia
TNFAIP3	Systemic lupus erythematosus, rheumatoid arthritis
JAZF1	Height, type 2 diabetes*
Intergenic	Prostate or colorectal cancer, breast cancer
CDKN2A, CDKN2B	Type 2 diabetes, intracranial aneurysm, myocardial infarction

Hindorff (2009) PNAS 106:9362

Types of associated variants



Hindorff (2009) PNAS 106:9362

Small proportion of variability currently explained by common variants

Table 1 | Estimates of heritability and number of loci for several complex traits

Disease	Number of loci	Proportion of heritability explained
Age-related macular degeneration[72]	5	50%
Crohn's disease[21]	32	20%
Systemic lupus erythematosus[73]	6	15%
Type 2 diabetes[74]	18	6%
HDL cholesterol[75]	7	5.2%
Height[15]	40	5%
Early onset myocardial infarction[76]	9	2.8%
Fasting glucose[77]	4	1.5%

* Residual is after adjustment for age, gender, diabetes.

Use of the current information in clinical practice will be disease dependent

Manolio (2009) Nature 46: 747

Prediction of height



Lettre et al. (2008) Nat Gen 40:584-591

Clinical translation



McCarthy (2008) Nat Rev Gen 9:356

Summary

- **Need careful attention to design and QC**
- **Need large samples to find small signals**
- **460 signals ($P \leq 5 \times 10^{-8}$) and counting**

- **Finding an association signal does not immediately yield information on the underlying biology or clinical utility**
- **Time to changes in medical care based on GWA results may be many years**

Future of GWA

- **More and more loci identified**
- **Larger meta-analyses**
- **Deeper follow-up of GWA signals**
- **Larger GWA panels with lower frequency**
- **More diverse populations**
- **Other sequence variants**
- **New phenotypes**
- **Gene-gene and -environment interactions**
- **Molecular and biological mechanisms**